Core Viewpoint - A class action lawsuit has been filed against CTO Realty Growth, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 18, 2021, to June 24, 2025, seeking damages for misleading statements regarding the company's financial health and dividend sustainability [1][6]. Company Overview - CTO Realty Growth, Inc. is a publicly traded real estate investment trust (REIT) that owns and operates a portfolio of retail-based properties primarily in higher growth markets in the U.S. The company converted to a REIT in February 2021 and owned 23 income properties across seven states as of December 31, 2024 [4]. - REITs are required to distribute at least 90% of their taxable profits as dividends to benefit from corporate income tax exemptions. CTO claims that its REIT structure allows for tax-efficient operations and sustainable dividends [5]. Allegations and Financial Concerns - The lawsuit alleges that CTO's dividends were less sustainable than represented, and the company used deceptive practices to inflate its Adjusted Funds from Operations (AFFO) and overstate profitability, particularly regarding the Ashford Lane property [6]. - A report by Wolfpack Research criticized CTO for not generating sufficient cash to cover recurring capital expenditures and dividends since its conversion to a REIT, indicating a reliance on share dilution to address a $38 million dividend shortfall from 2021 to 2024 [7]. - The report highlighted that CTO's AFFO definition excluded recurring capital expenditures, which is inconsistent with industry peers, and noted that the company faced significant financial challenges, including only $8.4 million in cash against quarterly dividends of $14 million and additional capital expenditures [7]. Market Reaction - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98 per share, or 5.42%, closing at $17.10 per share on June 25, 2025 [8].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Confluent, Inc. and its officers or directors, following a significant drop in the company's stock price after disappointing financial results [1][2]. Financial Performance - On July 30, 2025, Confluent announced its second-quarter financial results, revealing that consumption growth was negatively affected by ongoing optimization, with month-over-month trends lagging behind previous years [2]. - The company's stock price plummeted by $8.68 per share, or 32.86%, closing at $17.73 per share on July 31, 2025, in response to the earnings call and the CFO's comments regarding reduced usage of Confluent Cloud by an AI-native customer [2]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Confluent, indicating a potential class action lawsuit related to the alleged securities fraud [1]. - The firm has a long history of handling corporate, securities, and antitrust class litigation, emphasizing its commitment to fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Praxis Precision Medicines, Inc. and its officers or directors [1] Financial Results - On August 4, 2025, Praxis reported its financial results for Q2 2025, including mid-stage study results for its anti-seizure medication vormatrigine [2] - In the study, 36 out of 61 patients experienced treatment-emergent adverse events, and nearly 25% of participants discontinued the study [2] Stock Market Reaction - Following the announcement of the study results, Praxis's stock price decreased by $3.00 per share, or 5.55%, closing at $51.09 per share on August 4, 2025 [3]

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud following a significant decline in its financial performance, which has led to a sharp drop in its stock price [1][2][3]. Financial Performance - Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [2]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [2]. - Following the announcement of these results, Insperity's stock price fell by $14.51, or 24.35%, closing at $45.07 per share on August 1, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Novo Nordisk has significantly lowered its sales outlook for 2025 due to increased competition for its drugs Ozempic and Wegovy, leading to a substantial drop in its stock price [3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk reduced its sales forecast for 2025, attributing the change to heightened competition in the market for its key products [3]. - Following the announcement, Novo Nordisk's American Depositary Receipt (ADR) price decreased by $15.06, or 21.83%, closing at $53.94 per ADR on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or unlawful business practices by Novo Nordisk and its officers or directors [1].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Exelixis reported second-quarter financial results on July 28, 2025, revealing net product revenues for cabozantinib were approximately 2% below the consensus estimate of $531.3 million [2] - The company decided not to proceed to the phase 3 portion of the STELLAR-305 study in advanced squamous cell carcinoma due to emerging competition and assessment of other commercial opportunities [2] - Following the announcement, Exelixis's stock price fell by $7.45 per share, or 16.78%, closing at $36.94 per share on July 29, 2025 [2] Company Overview - Exelixis, Inc. is involved in the development and commercialization of innovative therapies for cancer treatment [2] - The company has faced scrutiny regarding its business practices and financial disclosures, leading to an investigation by Pomerantz LLP [1][2] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [3]

Core Viewpoint - Anika Therapeutics is under investigation for potential securities fraud following the announcement of disappointing clinical trial results for its product Hyalofast, which led to a significant drop in stock price [1][2]. Group 1: Company Overview - Anika Therapeutics, Inc. is a publicly traded company on NASDAQ under the ticker ANIK [1]. - The company focuses on developing innovative therapies for tissue regeneration and repair [2]. Group 2: Clinical Trial Results - On July 30, 2025, Anika announced topline results from a pivotal clinical trial of Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [2]. - The trial showed consistent improvements in treated patients compared to microfracture, but did not meet its pre-specified co-primary endpoints [2]. - Factors affecting the trial results included a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and a reduced evaluable sample size [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Anika's stock price fell by $3.06 per share, or 27.42%, closing at $8.10 per share on July 30, 2025 [2].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - JMP Securities has lowered its price target on Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [2] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 per share on July 28, 2025 [3]

Core Viewpoint - Charter Communications is under investigation for potential securities fraud and unlawful business practices following a significant decline in customer numbers and a sharp drop in stock price [1][2][3]. Financial Performance - In Q2 2025, Charter reported a decline of 117,000 total internet customers, which is a larger decrease compared to a decline of about 100,000 in Q2 2024 when adjusted for the Affordable Connectivity Program's end [2]. - The company also experienced a decrease of 80,000 total video customers during the same period [2]. Stock Market Reaction - Following the release of the disappointing financial results, Charter's stock price fell by $70.25 per share, representing an 18.5% decline, closing at $309.75 per share on July 25, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - Harrow reported Q1 2025 revenue of $47.8 million, which was below the consensus estimate of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [3]